Clinical trials for medicines: Declaration of Helsinki and Clinical Trial Regulations alignment

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has finalized updated guidance regarding the amended Clinical Trials Regulations, which reached full implementation on April 28, 2026. This regulatory framework establishes the legal requirements for conducting clinical trials within the United Kingdom, specifically emphasizing the role of the Declaration of Helsinki in trial ethics. A significant change in this update is the removal of references to specific versions of the Declaration; instead, trial sponsors are required to adhere to its general principles. The primary issue addressed is the potential for conflicts between these international ethical principles and the specific mandates of UK law. The guidance clarifies that while the principles of the Declaration of Helsinki are mandatory, they must not supersede the amended Regulations. In instances where a conflict exists, the MHRA requires sponsors to prioritize compliance with UK legislation. To ensure regulatory transparency, sponsors must take formal action by documenting the rationale for any deviations from the Declaration and evaluating the impact of these deviations on the trial. This ensures that clinical research remains ethically sound while strictly adhering to the updated national legal standards.